|Titulo||Austerity vs. growth--the impact of the current financial crisis on pharmaceutical innovation.|
|Autoría||Sharma D, Martini LG.|
|Fuente||Int J Pharm. 2013 Feb 25;443(1-2):242-4.|
Europe is in crisis. Society can no longer spend more than what it earns. This inevitably means that governments will have to better manage costly areas such as education and healthcare. In Europe, governments are forcing pharmaceutical companies to decrease the costs of medicinal drugs and therefore organisations are looking more closely at other growth regions like the Americas or Asia Pacific (Davis, 2010). The level of debt, just in Greece alone is unsustainable. After a while, millions appear to roll into billions and adding a few more zeros just doesn’t compute. It is beyond sense or, simply put, nonsense. Europe has to tighten its belt and this will impact innovation in Europe.
|Tipo de documento||Artículo cientifico|
|Impacto en el sistema sanitario||Otras medidas|
|Impacto en la salud||--|